Glen Eagle Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Glen Eagle Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.78K	Buy	200 +40	+25%	+$1.33K	﹤0.01%	750
2026 Q1	$4.82K	Hold	160	–	–	﹤0.01%	761
2025 Q4	$4.99K	Hold	160	–	–	﹤0.01%	776
2025 Q3	$3.23K	Hold	160	–	–	﹤0.01%	839
2025 Q2	$2.68K	Hold	160	–	–	﹤0.01%	814
2025 Q1	$2.46K	Hold	160	–	–	﹤0.01%	823
2024 Q4	$3.53K	Hold	160	–	–	﹤0.01%	796
2024 Q3	$2.88K	Hold	160	–	–	﹤0.01%	853
2024 Q2	$2.6K	Hold	160	–	–	﹤0.01%	863
2024 Q1	$2.26K	Hold	160	–	–	﹤0.01%	892
2023 Q4	$1.67K	Hold	160	–	–	﹤0.01%	883
2023 Q3	$1.63K	Hold	160	–	–	﹤0.01%	885
2023 Q2	$1.21K	Hold	160	–	–	﹤0.01%	940
2023 Q1	$1.42K	Hold	160	–	–	﹤0.01%	909
2022 Q4	$1.46K	Hold	160	–	–	﹤0.01%	951
2022 Q3	$1.29K	Buy	+160	New	+$1.42K	﹤0.01%	940
2021 Q1	–	Sell	-350	Closed	-$3.38K	–	1023
2020 Q4	$3.38K	Hold	350	–	–	﹤0.01%	791
2020 Q3	$3.15K	Hold	350	–	–	﹤0.01%	748
2020 Q2	$4.32K	Buy	350 +200	+133%	+$2.26K	﹤0.01%	689
2020 Q1	$1.35K	Buy	+150	New	+$1.54K	﹤0.01%	738
2019 Q1	–	Sell	-61	Closed	-$941	–	754
2018 Q4	$941	Hold	61	–	–	﹤0.01%	676
2018 Q3	$1.31K	Buy	+61	New	+$1.42K	﹤0.01%	657
2018 Q2	–	Sell	-100	Closed	-$1.71K	–	705
2018 Q1	$1.71K	Hold	100	–	–	﹤0.01%	605
2017 Q4	$1.9K	Sell	100 -850	-89%	-$12.8K	﹤0.01%	572
2017 Q3	$16.7K	Sell	950 -200	-17%	-$4.5K	0.02%	361
2017 Q2	$38.2K	Sell	1,150 -5,674	-83%	-$176K	0.03%	238
2017 Q1	$223K	Buy	6,824 +515	+8%	+$17.6K	0.19%	115
2016 Q4	$229K	Buy	+6,309	New	+$252K	0.21%	118

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Glen Eagle Advisors's TEVA Position: Q2 2026 in Review

Glen Eagle Advisors increased its Teva Pharmaceuticals (TEVA) stake by 25% in Q2 2026, buying an estimated $1.33K and bringing the position to 200 shares worth $6.78K. The position accounts for ﹤0.01% of the portfolio, ranked #750.

Glen Eagle Advisors first reported a position in TEVA in Q4 2016 and has held it in 28 quarters since. The position peaked at $229K in Q4 2016. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Glen Eagle Advisors held 200 shares of Teva Pharmaceuticals worth $6.78K as of Q2 2026.
Glen Eagle Advisors bought 40 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.33K.
Teva Pharmaceuticals made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #750 holding.
Glen Eagle Advisors first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 28 quarters since.
Glen Eagle Advisors's Teva Pharmaceuticals position peaked at $229K in Q4 2016.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.